Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 100.37% | -64.06% | 37.64% | -158.20% | -46.73% |
| Total Depreciation and Amortization | -3.03% | 0.78% | 1.12% | 0.23% | -0.11% |
| Total Amortization of Deferred Charges | 10.11% | 27.14% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -71.07% | -14.54% | -29.55% | 34.64% | 1,070.81% |
| Change in Net Operating Assets | -212.31% | 133.46% | -192.39% | -28.51% | -33.45% |
| Cash from Operations | 304.87% | 0.47% | -160.30% | -67.39% | -1.33% |
| Capital Expenditure | 65.80% | -7.58% | -26.82% | 22.29% | -282.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.57% | -118.10% | 203.81% | 281.82% | -25.54% |
| Cash from Investing | 58.06% | -342.58% | 303.56% | 78.79% | -164.59% |
| Total Debt Issued | -100.00% | 6.56% | 22.00% | 150.00% | 0.00% |
| Total Debt Repaid | 0.00% | 67.21% | 13.43% | -8.40% | 13.33% |
| Issuance of Common Stock | 973.33% | -92.06% | 1,160.00% | -92.72% | -- |
| Repurchase of Common Stock | -- | 100.00% | 74.47% | 97.73% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -164.50% | 1,088.70% | 116.78% | 74.37% | -49.67% |
| Foreign Exchange rate Adjustments | -198.11% | 9,150.00% | 102.65% | 17.49% | 5.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.48% | 351.69% | -639.29% | 97.35% | -204.04% |